Evaluation of the serum visfatin and adiponectin levels in patients with type 2 diabetes mellitus

Objective: The purpose of this study was to assess the levels of serum adiponectin and visfa- tin in patients with Type 2 Diabetes Mellitus and to investigate their potential roles in insulin resistance and obesity in T2DM. Methods: The study was carried out in 45 patients with T2DM and 20 sex and age matched healthy control subjects (n=20). According to the body mass index (BMI) 45 patients were divided into two subgroups; one group was nonobese diabetic patients with 18.50 < BMI < 24.99kg/m 2 (n=20) and the other group was type 2 diabetic obese diabetic patients with BMI ≥30kg/m 2 (n=25). Serum adiponectin and visfatin levels were determined by using ELISA (Enzyme-Linked Immuno-Sorbent Assay) method. The insulin resistance index was as- sessed by homeostasis model assessment for insulin resistance (HOMA-IR). Results: Serum adiponectin levels in obese and non-obese diabetic subjects was low when compared to the control group ( p<0.001 and p<0.01; respectively). Conversely adiponectin, visfatin levels compared with control was higher in obese diabetic (p<0.001). When adi- ponectin was negatively correlated with duration of diabetes, body mass index, HOMA-IR, HbA1c, and glucose, visfatin was positively correlated with HOMA-IR and body mass index. Conclusion: Diabetic patients compared with healthy control group decreased serum adipo- nectin and increased serum visfatin levels may be useful in the elucidation of the connection between obesity - insulin resistance.